tradingkey.logo

Bioventus Inc

BVS
View Detailed Chart

7.200USD

+0.270+3.90%
Close 09/18, 16:00ETQuotes delayed by 15 min
481.57MMarket Cap
LossP/E TTM

Bioventus Inc

7.200

+0.270+3.90%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.90%

5 Days

-1.10%

1 Month

+0.28%

6 Months

-24.69%

Year to Date

-31.43%

1 Year

-38.41%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
79 / 207
Overall Ranking
206 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
14.667
Target Price
+111.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Overvalued
The company’s latest PE is 218.78, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.37M shares, decreasing 12.51% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.77M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.49.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Ticker SymbolBVS
CompanyBioventus Inc
CEOMr. Robert E. Claypoole
Websitehttps://www.bioventus.com/
KeyAI